Penile Prosthesis Implantation Workup

  • Author: Richard A Santucci, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS   more...
 
Updated: Jan 23, 2012
 

Laboratory Studies

  • The workup of erectile dysfunction (ED) is controversial and not standardized among urologists. Some practitioners do not attempt to perform complex diagnostic procedures to determine the exact cause of the ED, reasoning that all organic impotence is treated in the same manner and that a specific diagnosis is not more helpful to the patient. Others, usually specialists in impotence, have a multitiered approach to the diagnosis of ED.
  • Endocrine disturbances are an important and potentially treatable cause of ED. The hypothalamic-pituitary-testicular axis is a very important and finely balanced force that helps regulate many bodily functions, including sexual drive and behavior. The hypothalamus secrets gonadotropin-releasing hormone that stimulates pituitary production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These in turn stimulate testicular function, including production of androgens such as testosterone and dihydrotestosterone. Both of these hormones are important for male genital fetal development, formation of male secondary sexual characteristics, and libido.
  • In developed adult men, testosterone greatly influences sexual behavior because (1) castrated men report decrease in sexual interest and performance, (2) hypogonadal men can have increased libido if supplemented with exogenous androgens, and (3) antiandrogens, such as those administered to treat prostate cancer, can greatly suppress sexual desire and performance in men.
  • The complete workup of ED should include a biochemical/hormonal profile to help delineate underlying endocrinopathies such as hypogonadism or hyperprolactinemia, which may be able to be managed medically.
  • Many clinicians investigate an initial testosterone level prior to sending a more exhaustive panel. Some specialists who focus on treating ED may elect to send a larger panel.
  • More extensive laboratory tests may include prolactin, free testosterone, and gonadotropin (both FSH and LH) in addition to a screening testosterone.
  • Of course, the first step to help a clinician investigate ED is a careful history and physical examination. In the physical examination, the clinician should be aware of secondary sexual characteristics, such as axillary and pubic hair distribution, as well as body habitus. In some instances, this provides clues about underlying endocrine problems.
  • When low levels of gonadotropins and testosterone are present, the clinician should be suspicious of a hypothalamopituitary cause and consider cranial imaging, such as MRI, to rule out pituitary or hypothalamic tumors or the empty sella syndrome.
  • Patients with thyroid problems experience sexual problems. Hyperthyroidism can cause decreased libido, most likely because of increased levels of circulating estrogens. Hypothyroidism can cause decreased testosterone levels and increased prolactin levels, causing erectile difficulties and decreased libido.
  • Some controversy exists regarding penile prosthesis implantation in persons with diabetes. Early studies indicated a high infection rate in persons with poorly controlled diabetes with elevated hemoglobin A1c levels. Subsequent studies challenged this practice, but, as mentioned above, the practice is not uniform. Persons with poorly controlled diabetes have a higher complication rate due to infection, compliance issues, and tissue healing. Therefore, their satisfaction rates are lower than those of persons without diabetes.
Next

Imaging Studies

Many practitioners do not feel that preoperative imaging studies are required before penile prosthesis implantation. However, others prefer a complete workup of the etiology of ED, which can include arteriography, penile duplex with Doppler flow, and cavernosography.

  • Arteriography
    • This study rarely is performed, and practitioners sometimes pose the question, "Is it worth all the trouble?"
    • Penile arteriography proves to be extremely challenging because of the wide variation in penile arterial anatomy. Often, selective catheterization of the intended pudendal arteries is not only difficult but also extremely time consuming. Over time, the artery can spasm and produce a false reading, and, sometimes, accessory internal pudendal arteries can mislead the true extent of penile inflow.
    • The best arteriograms should be performed with cavernosal arterial distention to view the cavernosal arteries in their entirety and then follow the arteriolar flow.
    • The cavernosal arteries in the flaccid state are 0.2-1 mm in diameter, which can increase to 1-1.5 mm. In most instances, the spatial resolution, even with modern angiographic instruments, can account for a 30% error rate in vessel diameter. Operator inconsistency can further increase the error rate.
    • Many pragmatic experts question the value of arteriography, especially when considering what patients must undergo, its high cost, and the limited information it provides. Most experts do agree that its most useful application is in patients with pelvic trauma who are young and may have discrete lesions that are amenable to vascular intervention, such as to repair steal syndrome or simply to cannulize or bypass an area of obstruction or stenosis.
  • Duplex sonography
    • Urologists specializing in ED often use the duplex sonography modality. It has some clear advantages over other diagnostic tests. It can be performed in an office setting and is noninvasive. Imaging is good, and Doppler blood flow studies can be accomplished on individual cavernous arteries. In addition to its ability to demonstrate the vascular state of penile vessels, it also can reveal a venous leak, high-flow priapism, and calcium deposits characteristic of Peyronie disease.
    • The study entails first obtaining baseline images and measurement on the flaccid penis; then, a pharmacologic agent is injected to induce erection. Cavernous arterial diameter and pulsatility are recorded, as well as any anomalous anatomy or findings. This information allows the urologist objective criteria concerning flow velocity and arterial caliber to gauge vascular health.
    • Some authors agree that a peak systolic velocity of greater than 35 cm/s indicates a normal arterial supply, and those with a velocity of less than 25 cm/s are considered to have severe arterial disease. More subjective is the pulsatility or ability to dilate regarding penile arteries. Most experts agree that, in general, a forceful pulsation with good change in arterial diameter between systolic and diastolic phases indicates normal arterial function and signals a healthy arterial system.
    • Proponents of duplex ultrasonography say that it is an effective modality to evaluate vasculogenic impotence. However, it also has problems that can affect accuracy; the procedure is performed in a nonsexual office setting, patients vary in their response to vasogenic agents in both dosage and time to erection, and the test is very operator-dependent.
  • Cavernosography
    • This study uses radiocontrast solution injected into the corpora cavernosa during an artificial erection. The injection is a percutaneous intracorporal infusion of fluid via a needle or catheter. It should always be performed after a vasoactive agent is injected in an attempt to induce erection.
    • By performing this study, clinicians hope to visualize areas of venous leak, where blood normally trapped during erections leaks out so that arterial inflow cannot maintain adequate erections.
    • Areas of leak include the glans, corpus spongiosum, superficial and deep veins, cavernous veins, and areas of Peyronie plaque. The original thought was that if these areas could be ligated surgically, erectile function could begin to favor arterial inflow. However, enthusiasm for cavernosography and venous ligation has waned because of poor long-term results.
Previous
Next

Diagnostic Procedures

  • Nocturnal penile tumescence testing
    • The NPT test takes advantage of the natural sleep-related erections found in potent men during rapid eye movement (REM) sleep. The primary goal of NPT testing is to distinguish organic etiology from psychogenic causes of ED.
    • NPT testing was once associated with a wide assortment of tests, including those for sleep study, such as electroencephalography, electro-oculography, electromyography, and video monitoring. Today, many urologists use an abbreviated portable home model (RigiScan), which a patient can take home after he is instructed on its proper use. Essentially, it entails applying a measuring device to the penis that measures the number of nocturnal erections, axial rigidity at base and tip, duration of erection, and level of maximal rigidity.
    • NPT testing and the introduction of the portable RigiScan for home use in 1985 still have some controversies, particularly regarding the lack of standardized parameters and limited clinical trials.
    • Cilurzo et al (1992) suggest the following for normal NPT parameters:[7]
      • Achieving 4-5 erectile episodes per night
      • Mean duration of erectile episodes greater than 30 minutes
      • Increase in circumference of greater than 3 cm at base and 2 cm at tip during erectile episodes
      • Greater than 70% maximal rigidity at both tip and base during erectile episodes
    • NPT testing, although expensive, can help differentiate organic from psychogenic impotence and thus prevent further unnecessary workup and possible unwarranted intervention.
Previous
 
 
Contributor Information and Disclosures
Author

Richard A Santucci, MD, FACS  Specialist-in-Chief, Department of Urology, Detroit Medical Center; Chief of Urology, Detroit Receiving Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State University College of Medicine

Richard A Santucci, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, and Société Internationale d'Urologie (International Society of Urology)

Disclosure: Nothing to disclose.

Coauthor(s)

Nazia Q Bandukwala, DO  Resident Physician, Department of Urology, Detroit Medical Center

Nazia Q Bandukwala, DO is a member of the following medical societies: American College of Osteopathic Surgeons, American Osteopathic Association, American Urological Association, and Sigma Sigma Phi

Disclosure: Nothing to disclose.

Curtis N Crane, MD  Fellow in Genitourinary Trauma and Reconstructive Urology, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Gamal Mostafa Ghoniem, MD, FACS  Professor of Urology, Chief, Division of Female Urology, Pelvic Reconstructive Surgery, and Voiding Dysfunction, Department of Urology, University of California, Irvine, School of Medicine

Gamal Mostafa Ghoniem, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urogynecologic Society, American Urological Association, International Continence Society, International Urogynaecology Association, and Society of Urodynamics and Female Urology

Disclosure: Astellas Honoraria Speaking and teaching; Coloplasty Consulting fee Board membership; Uroplasty Consulting fee Consulting

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Shlomo Raz, MD  Professor, Department of Surgery, Division of Urology, University of California at Los Angeles School of Medicine

Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, and California Medical Association

Disclosure: Nothing to disclose.

J Stuart Wolf Jr, MD, FACS  The David A Bloom Professor of Urology, Director, Division of Endourology and Stone Disease, Department of Urology, University of Michigan Medical School

J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology

Disclosure: Nothing to disclose.

Chief Editor

Bradley Fields Schwartz, DO, FACS  Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous coauthors Yao-Jen Chang, MD, and Christopher Knopick, MD, to the development and writing of this article.

References
  1. Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology. Jul 1973;2(1):80-2. [Medline].

  2. Pearman RO. Treatment of organic impotence by implantation of a penile prosthesis. J Urol. Apr 1967;97(4):716-9. [Medline].

  3. Carson CC 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol. Apr 2004;171(4):1611-4. [Medline].

  4. Massey FJ Jr, Bernstein GS, O'Fallon WM, Schuman LM, Coulson AH, Crozier R, et al. Vasectomy and health. Results from a large cohort study. JAMA. Aug 24-31 1984;252(8):1023-9. [Medline].

  5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. Jan 1994;151(1):54-61. [Medline].

  6. [Best Evidence] Rosenberg MT, Adams PL, McBride TA, Roberts JN, McCallum SW. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract. Jan 2009;63(1):27-34. [Medline].

  7. Cilurzo P, Canale D, Turchi P, Giorgi PM, Menchini Fabris GF. [The Rigiscan system in the diagnosis of male sexual impotence]. Arch Ital Urol Nefrol Androl. Jun 1992;64 Suppl 2:81-5. [Medline].

  8. Henry G, Houghton L, Culkin D, Otheguy J, Shabsigh R, Ohl DA. Comparison of a new length measurement technique for inflatable penile prosthesis implantation to standard techniques: outcomes and patient satisfaction. J Sex Med. Sep 2011;8(9):2640-6. [Medline].

  9. Pathak AS, Chang JH, Parekh AR, Aboseif SR. Use of Rectus Fascia Graft for Corporeal Reconstruction During Placement of Penile Implant. Urology. Jun 05;65:1198-201.

  10. Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol. Feb 2000;163(2):481-2. [Medline].

  11. Akin-Olugbade O, Parker M, Guhring P, Mulhall J. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. Jul 2006;3(4):743-8. [Medline].

  12. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol. May 1996;155(5):1609-12. [Medline].

  13. Henry GD, Donatucci CF, Conners W, Greenfield JM, Carson CC, Wilson SK, et al. An Outcomes Analysis of over 200 Revision Surgeries for Penile Prosthesis Implantation: A Multicenter Study. J Sex Med. Nov 14 2011;[Medline].

  14. Goldstein I, Newman L, Baum N, Brooks M, Chaikin L, Goldberg K, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol. Mar 1997;157(3):833-9. [Medline].

  15. Dhar NB, Angermeier KW, Montague DK. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J Urol. Dec 2006;176(6 Pt 1):2599-601; discussion 2601. [Medline].

  16. Lux M, Reyes-Vallejo L, Morgentaler A, Levine LA. Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. J Urol. Jan 2007;177(1):262-6. [Medline].

  17. Wilson SK, Henry GD, Delk JR Jr, Cleves MA. The mentor Alpha 1 penile prosthesis with reservoir lock-out valve: effective prevention of auto-inflation with improved capability for ectopic reservoir placement. J Urol. Oct 2002;168(4 Pt 1):1475-8. [Medline].

  18. Abouassaly R, Angermeier KW, Montague DK. Risk of infection with an antibiotic coated penile prosthesis at device replacement for mechanical failure. J Urol. Dec 2006;176(6 Pt 1):2471-3. [Medline].

  19. Rajpurkar A, Al-Omar O, Hellstrom WJ, et al. Polypyrrolidone-coated bioflex decreases infection rate following penile prosthesis surgery. Int J Impot Res. 2003;15:s163.

  20. Becher E, Borghi M, de Oca LM, et al. Improvement of penile glans engorgement in patients with penile implants using topical alprostadil. Int J Impot Res. 2003;15:s11.

  21. Anderson P, Agarwal V, Soden F, Ralph D, Minhas S. Outcome from Penile Prostheses Revision Surgery: MP-04-126. Journal of Sexual Medicine. 2007;4S2:146.

  22. Beutler LE, Scott FB, Rogers RR Jr, Karacan I, Baer PE, Gaines JA. Inflatable and noninflatable penile prostheses: comparative follow-up evaluation. Urology. Feb 1986;27(2):136-43. [Medline].

  23. Brinkman MJ, Henry GD, Wilson SK, Delk JR 2nd, Denny GA, Young M, et al. A survey of patients with inflatable penile prostheses for satisfaction. J Urol. Jul 2005;174(1):253-7. [Medline].

  24. Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res. Oct 2003;15 Suppl 5:S139-46. [Medline].

  25. Carson CC, Hodge GB, Anderson EE. Penile prosthesis in Peyronie's disease. Br J Urol. Aug 1983;55(4):417-21. [Medline].

  26. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol. Aug 2000;164(2):376-80. [Medline].

  27. Chiang HS, Wu CC, Wen TC. 10 years of experience with penile prosthesis implantation in Taiwanese patients. J Urol. Feb 2000;163(2):476-80. [Medline].

  28. Drogo K. Montague and Kenneth W. Angermeier. Corporeal Excavation: New Technique for Penile Prosthesis Implantation in Men with Severe Corporeal Fibrosis. Urology. 2006;67:1072-1075.

  29. Jarow JP. Risk factors for penile prosthetic infection. J Urol. Aug 1996;156(2 Pt 1):402-4. [Medline].

  30. Knoll LD, Furlow WL, Benson RC Jr. Management of Peyronie disease by implantation of inflatable penile prosthesis. Urology. Nov 1990;36(5):406-9. [Medline].

  31. Lotan Y, Roehrborn CG, McConnell JD, Hendin BN. Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology. Nov 2003;62(5):918-21. [Medline].

  32. Montague DK. Periprosthetic infections. J Urol. Jul 1987;138(1):68-9. [Medline].

  33. Montague DK, Angermeir KW. Surgical approaches for penile prosthesis implantation: penoscrotal vs infrapubic. Int J Impot Res. Oct 2003;15 Suppl 5:S134-5. [Medline].

  34. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. Jul 2005;174(1):230-9. [Medline].

  35. Silverstein AD, Henry GD, Evans B, Pasmore M, Simmons CJ, Donatucci CF. Biofilm formation on clinically noninfected penile prostheses. J Urol. Sep 2006;176(3):1008-11. [Medline].

  36. Staerman FS, Menard JM, Faix AF, Tremeaux J. Penile Prosthesis and Impotence in Elderly Men: Results of a Multicenter Study After 79 Implantations: MP-088. Journal of Sexual Medicine. 2006;3S5:432-433.

  37. Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell's Urology. Vol 2. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002.

Previous
Next
 
Exposure of the corpus cavernosum followed by placement of stay sutures in the walls of the corpus followed by corporotomy in anticipation of placing an intracavernosal rod. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Proximal dilation of the corpus with Hegar dilator. (Photograph courtesy of Chirpraya B. Dhabuwala, MD)
Seating of the proximal portion of the prosthesis into the corpus. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Seating the distal portion of the prosthesis into the distal corpus using the suture attached to the prosthesis. Previously, the suture has been passed out the glans penis using a Furlow inserter. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
Bluntly creating the subdartos pouch, which will house the pump. (Photograph courtesy of Chirpraya B. Dhabuwala, MD).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.